KR102513872B1 - Adamts13의 피하 투여 - Google Patents

Adamts13의 피하 투여 Download PDF

Info

Publication number
KR102513872B1
KR102513872B1 KR1020227005350A KR20227005350A KR102513872B1 KR 102513872 B1 KR102513872 B1 KR 102513872B1 KR 1020227005350 A KR1020227005350 A KR 1020227005350A KR 20227005350 A KR20227005350 A KR 20227005350A KR 102513872 B1 KR102513872 B1 KR 102513872B1
Authority
KR
South Korea
Prior art keywords
adamts13
mammal
administered
hours
discovery
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020227005350A
Other languages
English (en)
Korean (ko)
Other versions
KR20220027266A (ko
Inventor
알렉산드라 나탈리 코픽
베르너 횔리에글
바바라 플라이마우어
한스페터 로텐스타이너
에바-마리아 무치쉬
Original Assignee
박스알타 인코퍼레이티드
박스앨타 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 박스알타 인코퍼레이티드, 박스앨타 게엠베하 filed Critical 박스알타 인코퍼레이티드
Publication of KR20220027266A publication Critical patent/KR20220027266A/ko
Application granted granted Critical
Publication of KR102513872B1 publication Critical patent/KR102513872B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24087—ADAMTS13 endopeptidase (3.4.24.87)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
KR1020227005350A 2013-03-15 2014-03-13 Adamts13의 피하 투여 Active KR102513872B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361794659P 2013-03-15 2013-03-15
US61/794,659 2013-03-15
PCT/US2014/026747 WO2014151968A1 (en) 2013-03-15 2014-03-13 Subcutaneous administration of adamts13
KR1020217004442A KR102365936B1 (ko) 2013-03-15 2014-03-13 Adamts13의 피하 투여

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020217004442A Division KR102365936B1 (ko) 2013-03-15 2014-03-13 Adamts13의 피하 투여

Publications (2)

Publication Number Publication Date
KR20220027266A KR20220027266A (ko) 2022-03-07
KR102513872B1 true KR102513872B1 (ko) 2023-03-27

Family

ID=50549463

Family Applications (5)

Application Number Title Priority Date Filing Date
KR1020197005635A Active KR102102087B1 (ko) 2013-03-15 2014-03-13 Adamts13의 피하 투여
KR1020207010406A Active KR102218489B1 (ko) 2013-03-15 2014-03-13 Adamts13의 피하 투여
KR1020217004442A Active KR102365936B1 (ko) 2013-03-15 2014-03-13 Adamts13의 피하 투여
KR1020227005350A Active KR102513872B1 (ko) 2013-03-15 2014-03-13 Adamts13의 피하 투여
KR1020157028432A Ceased KR20160016756A (ko) 2013-03-15 2014-03-13 Adamts13의 피하 투여

Family Applications Before (3)

Application Number Title Priority Date Filing Date
KR1020197005635A Active KR102102087B1 (ko) 2013-03-15 2014-03-13 Adamts13의 피하 투여
KR1020207010406A Active KR102218489B1 (ko) 2013-03-15 2014-03-13 Adamts13의 피하 투여
KR1020217004442A Active KR102365936B1 (ko) 2013-03-15 2014-03-13 Adamts13의 피하 투여

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020157028432A Ceased KR20160016756A (ko) 2013-03-15 2014-03-13 Adamts13의 피하 투여

Country Status (18)

Country Link
US (4) US9611467B2 (enExample)
EP (2) EP3960196A1 (enExample)
JP (4) JP6484216B2 (enExample)
KR (5) KR102102087B1 (enExample)
CN (2) CN114259558A (enExample)
AU (5) AU2013203062C1 (enExample)
BR (1) BR112015023542A8 (enExample)
CA (1) CA2905058A1 (enExample)
DK (1) DK2968483T3 (enExample)
EA (2) EA034546B1 (enExample)
ES (1) ES2906550T3 (enExample)
IL (3) IL241305B (enExample)
MX (2) MX380485B (enExample)
PL (1) PL2968483T3 (enExample)
PT (1) PT2968483T (enExample)
SG (3) SG10201707074TA (enExample)
TW (4) TWI690326B (enExample)
WO (1) WO2014151968A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013203062C1 (en) * 2013-03-15 2018-06-28 Takeda Pharmaceutical Company Limited Subcutaneous administration of adamts13
GB201510870D0 (en) * 2015-05-26 2015-08-05 Baxalta Inc And Katholieke Universiteit Leuven And Baxalta Gmbh Treatment of infarction
CN116159130B (zh) 2016-08-04 2025-09-09 武田药品工业株式会社 使用adamts13治疗、改善和/或预防镰状细胞病、急性肺损伤和/或急性呼吸窘迫综合征中的血管阻塞危象
WO2020214033A1 (en) * 2019-04-17 2020-10-22 Erasmus University Medical Center Rotterdam Papain-like cysteine peptidase medicaments and uses thereof
WO2021067668A1 (en) 2019-10-04 2021-04-08 The Children's Medical Center Corporation Adamts13 treatment to enhance graft survival
US20230203469A1 (en) * 2020-04-02 2023-06-29 Takeda Pharmaceutical Company Limited Adamts13 variant, compositions, and uses thereof
WO2021234458A1 (en) 2020-05-22 2021-11-25 Takeda Pharmaceutical Company Limited Adamts13 compositions and methods for treating and diagnosing complications of coronavirus disease
KR20230038658A (ko) * 2020-05-25 2023-03-21 산퀸 아이피 비.브이. Adamts13 단백질 변형체 및 그것의 용도
JP2023549878A (ja) * 2020-11-18 2023-11-29 グリーン・クロス・コーポレイション 自己抗体に対する回避率又は活性が向上したａｄａｍｔｓ１３バリアント
GB202102208D0 (en) * 2021-02-17 2021-03-31 Univ Manchester Adamts13 variant
WO2024151093A1 (ko) * 2023-01-11 2024-07-18 주식회사 녹십자 혈전성 질환의 예방 또는 치료를 위한 신규한 액상 제형물

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006133955A1 (en) * 2005-06-17 2006-12-21 Baxter International Inc. Adamts13-comprising compositions having thrombolytic activity

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL113010A (en) 1994-03-31 1999-10-28 Pharmacia & Upjohn Ab Pharmaceutical formulation comprising factor viii with an activity of at least 500iu/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration
US6926894B2 (en) 2000-11-22 2005-08-09 Baxter Aktiengesellschaft Composition exhibiting a von willebrand factor (vWF) protease activity comprising a polypeptide chain with the amino acid sequence AAGGILHLELLV
US7037658B2 (en) * 2001-08-16 2006-05-02 Regents Of University Of Michigan Methods and compositions for detecting variant ADAMTS13 genes
US7763430B2 (en) 2003-04-22 2010-07-27 Baxter International Inc. Diagnostic assay for anti-von Willebrand Factor cleaving protease (ADAMTS13) antibodies
JP2009539757A (ja) * 2006-06-16 2009-11-19 バクスター・インターナショナル・インコーポレイテッド 血栓溶解活性を有するａｄａｍｔｓ１３含有組成物
US20090317375A1 (en) * 2008-05-12 2009-12-24 Immune Disease Institute, Inc. Von willebrand factor (vwf) inhibitors for treatment or prevention of infarction
AU2010284977A1 (en) * 2009-08-20 2012-03-29 Csl Behring Gmbh Albumin fused coagulation factors for non-intravenous administration in the therapy and prophylactic treatment of bleeding disorders
PL4218797T3 (pl) * 2009-09-21 2025-02-10 Takeda Pharmaceutical Company Limited Stabilizowane płynne i liofilizowane preparaty adamts13
CN103097522A (zh) * 2010-07-08 2013-05-08 巴克斯特国际公司 在细胞培养物中生产重组adamts13的方法
AU2013203062C1 (en) * 2013-03-15 2018-06-28 Takeda Pharmaceutical Company Limited Subcutaneous administration of adamts13

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006133955A1 (en) * 2005-06-17 2006-12-21 Baxter International Inc. Adamts13-comprising compositions having thrombolytic activity

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Current Opinion in Molecular Therapeutics. 2010 12(4) 461-470*
Thromb Haemost. 1999 Jan, 81(1) 8-13.*

Also Published As

Publication number Publication date
MX2015012783A (es) 2016-04-28
AU2013203062A1 (en) 2014-10-02
MX380485B (es) 2025-03-12
AU2022211908B2 (en) 2023-11-30
CN105407912A (zh) 2016-03-16
IL241305B (en) 2020-04-30
BR112015023542A2 (pt) 2017-07-18
CN114259558A (zh) 2022-04-01
EP2968483B1 (en) 2021-12-01
IL273365B (en) 2022-05-01
US10413600B2 (en) 2019-09-17
US20220080032A1 (en) 2022-03-17
AU2016231547B2 (en) 2018-03-15
KR20160016756A (ko) 2016-02-15
SG10201707074TA (en) 2017-10-30
US11185575B2 (en) 2021-11-30
JP7238088B2 (ja) 2023-03-13
NZ712440A (en) 2020-11-27
TW202313664A (zh) 2023-04-01
EP2968483A1 (en) 2016-01-20
IL273365A (en) 2020-05-31
IL290486B2 (en) 2023-08-01
AU2013203062B2 (en) 2016-06-23
TW201513881A (zh) 2015-04-16
KR102218489B1 (ko) 2021-02-22
AU2020202738A1 (en) 2020-05-14
AU2020202738B2 (en) 2022-06-09
SG11201507271QA (en) 2015-10-29
NZ751610A (en) 2020-11-27
KR20200041394A (ko) 2020-04-21
WO2014151968A8 (en) 2015-10-15
AU2018203665B2 (en) 2020-01-30
CA2905058A1 (en) 2014-09-25
TWI786563B (zh) 2022-12-11
JP2019142850A (ja) 2019-08-29
SG10202001227QA (en) 2020-03-30
HK1220131A1 (zh) 2017-04-28
EA201992832A1 (ru) 2020-05-31
KR20220027266A (ko) 2022-03-07
PL2968483T3 (pl) 2022-04-04
IL290486B1 (en) 2023-04-01
TWI740207B (zh) 2021-09-21
TW202017591A (zh) 2020-05-16
BR112015023542A8 (pt) 2019-12-03
IL290486A (en) 2022-04-01
KR20210021107A (ko) 2021-02-24
EP3960196A1 (en) 2022-03-02
KR20190022926A (ko) 2019-03-06
WO2014151968A1 (en) 2014-09-25
IL241305A0 (en) 2015-11-30
AU2016231547A1 (en) 2016-10-06
EA034546B1 (ru) 2020-02-19
US20140271611A1 (en) 2014-09-18
TWI690326B (zh) 2020-04-11
JP6998333B2 (ja) 2022-02-10
TW202138003A (zh) 2021-10-16
JP6484216B2 (ja) 2019-03-13
US11779635B2 (en) 2023-10-10
JP2022027991A (ja) 2022-02-14
US9611467B2 (en) 2017-04-04
KR102102087B1 (ko) 2020-04-20
US20170224785A1 (en) 2017-08-10
MX2021002513A (es) 2021-04-28
KR102365936B1 (ko) 2022-02-23
PT2968483T (pt) 2022-02-23
US20200101144A1 (en) 2020-04-02
JP2023071821A (ja) 2023-05-23
EA201591758A8 (ru) 2017-03-31
DK2968483T3 (da) 2022-02-14
AU2022211908A1 (en) 2022-09-01
ES2906550T3 (es) 2022-04-19
AU2018203665A1 (en) 2018-06-14
AU2013203062C1 (en) 2018-06-28
EA201591758A1 (ru) 2016-03-31
NZ749570A (en) 2020-11-27
JP2016517421A (ja) 2016-06-16

Similar Documents

Publication Publication Date Title
AU2022211908B2 (en) Subcutaneous administration of adamts13
HK40069281A (en) Subcutaneous administration of adamts13
EA045023B1 (ru) Подкожное введение adamts13
NZ712440B2 (en) Subcutaneous administration of adamts13
NZ749570B2 (en) Subcutaneous administration of adamts13

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20220217

Application number text: 1020217004442

Filing date: 20210215

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20220311

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20220517

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20221011

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20220517

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20221011

Comment text: Decision to Refuse Application

PX0701 Decision of registration after re-examination

Patent event date: 20230221

Comment text: Decision to Grant Registration

Patent event code: PX07013S01D

Patent event date: 20230213

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20221011

Comment text: Decision to Refuse Application

Patent event code: PX07011S01I

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20230321

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20230322

End annual number: 3

Start annual number: 1

PG1601 Publication of registration